Skip to Content
MilliporeSigma
All Photos(1)

Documents

PZ0006

Sigma-Aldrich

Exemestane

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
6-Methyleneandrosta-1,4-diene-3,17-dione
Empirical Formula (Hill Notation):
C20H24O2
CAS Number:
107868-30-4
Molecular Weight:
296.40
MDL number:
MFCD00866994
UNSPSC Code:
51111800
PubChem Substance ID:
329823675
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +250 to +300°, c = 1 in methanol

color

white to off-white

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

InChI key

BFYIZQONLCFLEV-DAELLWKTSA-N

Gene Information

human ... CYP19A1(1588)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

hcodes

H360,H411

Hazard Classifications

Aquatic Chronic 2 - Repr. 1B

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 7

1 of 7

vibrant-m

Y0001522

Anastrozole

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

Fadrozole hydrochloride ≥98% (HPLC)

Sigma-Aldrich

F3806

Fadrozole hydrochloride

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Letrozole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1540

Letrozole

Raloxifene hydrochloride solid

Sigma-Aldrich

R1402

Raloxifene hydrochloride

Elizabeth Maunsell et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(14), 1427-1436 (2014-04-09)
Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
Nan Soon Wong et al.
Expert opinion on pharmacotherapy, 6(13), 2353-2363 (2005-10-13)
Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast
Jürg Bernhard et al.
The Lancet. Oncology, 16(7), 848-858 (2015-06-21)
The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian function suppression (OFS) compared with tamoxifen plus OFS. We present patient-reported outcomes from these trials. Between Nov 7, 2003, and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service